Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy

Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α inhibitor (TNFi) approved for the treatment of ankylosing spondylitis (AS) in the USA and for AS and non-radiographic axial spondyloarthritis (nr-axSpA) in Europe and in some Latin American countries. CZP lacks Fc region, prev...

Descripción completa

Detalles Bibliográficos
Autores principales: Marin, Josefina, Acosta Felquer, María Laura, Soriano, Enrique R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944451/
https://www.ncbi.nlm.nih.gov/pubmed/29765257
http://dx.doi.org/10.2147/OARRR.S116654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944451/
https://www.ncbi.nlm.nih.gov/pubmed/29765257
http://dx.doi.org/10.2147/OARRR.S116654

Ejemplares similares